Salarius Pharmaceuticals reports FY24 EPS ($5.79) vs. ($30.74) last year

“We are pleased with the progress we are making with Decoy on the business combination transaction. We believe Decoy’s IMP3ACT platform with its ability to develop novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer offers both near- and long-term value for our shareholders,” said David Arthur, President, CEO and Director of Salarius Pharmaceuticals (SLRX). “As previously announced, the MDACC investigator-initiated hematologic cancer trial is active and enrolling patients, and we look forward to their clinical trial updates later this year.”